Superworth

Ocular Therapeutix price to book ratio OCUL

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
2.7×
10-year median
5.2×
Against its 10-year history
4th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.8× to 133×
Peer median
2.4×

Ocular Therapeutix's price to book ratio is 2.7× as of Oct 23, 2026.

That is below its ten-year median of 5.2×, lower than on 96% of days in the last ten years.

Over that time it ranged from 1.8× in Nov 2016 to 133× in Oct 2020.

The median for 10 large drugmakers of a similar size is 2.4×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.7×2.5×9.8×
202510.4×3.1×12.0×
20243.8×1.9×109×
202345.1×6.1×112×
20224.7×3.0×7.0×
20216.1×5.4×20.8×
2020112×18.5×133×
201917.8×3.2×25.6×
20183.7×3.7×10.1×
20173.6×2.6×5.5×
20163.3×1.4×4.6×
20152.3×1.6×15.5×
20147.5×5.1×7.5×

Against its peers

Companies in Drug Manufacturers - General nearest Ocular Therapeutix's size, closest first, today.

CompanyPrice to book ratio
OCULOcular Therapeutix2.7×
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
PAHCPhibro Animal Health4.1×
ANIPANI Pharmaceuticals2.8×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.4×
HRMYHarmony Biosciences2.1×
PBHPrestige Consumer Healthcare1.2×
ABUSArbutus Biopharma3.2×
COLLCollegium Pharmaceutical2.4×
Peer median2.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Ocular Therapeutix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.